Placebo-adjusted mean weight loss of 11.3% (27.3 lbs) with 120 mg dose in the 36-week Phase 2b ACCESS study with a 10.4% adverse event-related ...

Discover why Structure Therapeutics Inc. is rated Strong Buy after positive Aleniglipron phase 2b obesity data. Click for ...

Structure Therapeutics (GPCR) announced positive topline data from the ACCESS clinical program of aleniglipron for the treatment of people living ...

Investing.com -- Structure Therapeutics Inc ADR (NASDAQ:GPCR) stock soared 28.8% in premarket trading Monday after the company announced positive topline data from its ACCESS clinical program for ...

How Workforce Pell and OECD skills data are reshaping noncredit education, short-term credentials, and college-to-career ...

The company stated that results from aleniglipron achieved a mean weight loss of 11.3% at 36 weeks in the Phase 2b ACCESS ...

Structure Therapeutics stock soars 103% as its oral obesity drug aleniglipron shows strong Phase 2b weight-loss results.

AI visibility isn’t mysterious. It’s just another version of what SEO has always been: helping machines and humans understand the same thing.

Discover why Terns Pharmaceuticals, Inc. stock is up 770% YTD with strong CML drug data and major upcoming milestones. Click ...

Drillholes CMV25001 through 25004 have intercepted multiple zones of shallow, massive sulphide and quartz-sulphide, vein-hosted mineralization in the hanging and footwall of the SW dipping Chumavichi ...

Notre Dame has seen its College Football Playoff hopes dismantled, has declined its bowl game, and watched its relationship with the ACC deteriorate, all in the ...

On the policy front, the White House released an executive order 6 in February 2025 calling for the strengthening of price transparency initiatives in health care. In May 2025, the departments of HHS, ...